Drug Type Small molecule drug |
Synonyms EBI 2511, EBI2511 |
Target |
Mechanism EZH2 inhibitors(Histone-lysine N-methyltransferase EZH2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC34H48N4O4 |
InChIKeyNYWVSLBALKNFJR-UHFFFAOYSA-N |
CAS Registry2098546-05-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Preclinical | US | 19 Jan 2018 | |
Non-Hodgkin Lymphoma | Preclinical | CN | 19 Jan 2018 |